Serina Therapeutics (SER)
:SER
SER Stock Chart & Stats
$1.68
<$0.01(0.21%)
At close: 4:00 PM EST
$1.68
<$0.01(0.21%)
Day’s Range― - ―
52-Week Range$1.22 - $7.92
Previous CloseN/A
Volume4.86K
Average Volume (3M)24.47K
Market Cap
$32.68M
Enterprise Value$25.29M
Total Cash (Recent Filing)$3.06M
Total Debt (Recent Filing)$196.00K
Price to Earnings (P/E)―
Beta-0.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,785,564
10 Day Avg. Volume14,098
30 Day Avg. Volume24,472
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-526.02
Price to Sales (P/S)149.71
P/FCF Ratio-1.08
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue194.54
Enterprise Value/Gross Profit316.13
Enterprise Value/Ebitda-1.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentSER-252 will advance into and through clinical development, achieving comparable efficacy to currently approved infusion systems with improved tolerability and ease of use in advanced Parkinson's Disease patients.
Pipeline ExpansionSerina has announced a new once-weekly injectable asset in development for tardive dyskinesia, highlighting its POZ platform potential.
Regulatory PathwayThe FDA's feedback supports the design of the trial under the 505(b)(2) NDA pathway, which could fast-track SER-252's regulatory path by allowing the company to use existing knowledge of apomorphine.
Bears Say
Regulatory ChallengesThe FDA placed the IND for SER-252 in Parkinson's disease on clinical hold pending additional information on a commonly used formulation excipient.
Serina Therapeutics News
SER FAQ
What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was $1.22 and its highest was $7.92 in the past 12 months.
What is Serina Therapeutics’s market cap?
Serina Therapeutics’s market cap is $32.68M.
When is Serina Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Serina Therapeutics’s earnings last quarter?
Currently, no data Available
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Overvalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 10,785,564 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Serina Therapeutics?
Currently, no hedge funds are holding shares in SER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Serina Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth $240.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.4%
Last 30 Days ▲ 14.8%
Last 30 Days ▲ 14.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.74%
12-Months-Change
Fundamentals
Return on Equity
-1259.21%
Trailing 12-Months
Asset Growth
66.95%
Trailing 12-Months
Company Description
Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Technical Analysis
Outlook Therapeutics
―
Skye Bioscience
―
Celularity
―
Barinthus Biotherapeutics
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
1.51% Insiders
1.72% Mutual Funds
0.34% Other Institutional Investors
94.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---